Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News GlaxoSmithKline’s Eperzan diabetes drug gets EU green light

GlaxoSmithKline’s Eperzan diabetes drug gets EU green light

28th March 2014

GlaxoSmithKline has been granted approval to launch its once-weekly diabetes treatment Eperzan in the European Union later this year, the company has announced.

The European Medicines Agency (EMA) has given the green light to the treatment to improve glucose control in patients with type 2 diabetes, both as a monotherapy when diet and exercise alone are insufficient and metformin is not appropriate, and also in combination with other drugs, including insulin.

Eperzan is a GLP-1 agonist and as such will compete with the market-leading Victoza and Byetta treatments, produced by Novo Nordisk and AstraZeneca respectively. Both of these are administered daily. 

Novo Nordisk attempted to develop a weekly formulation of Victoza in 2012, but ended trials early when it became apparent the treatment was not as effective as a daily dosage.

Eli Lilly has submitted its once-weekly dulaglutide drug for regulatory consideration, while Sanofi is also preparing to formally seek approval for its long-acting lixisenatide treatment.ADNFCR-8000103-ID-801707559-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.